sb 203580 has been researched along with ginsenoside rg3 in 1 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (ginsenoside rg3) | Trials (ginsenoside rg3) | Recent Studies (post-2010) (ginsenoside rg3) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 443 | 9 | 322 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bae, HB; Choi, JI; Jang, EA; Jeong, S; Kim, DH; Kim, J; Lee, CH; Quan, H; Xin, C; Yin, M | 1 |
1 other study(ies) available for sb 203580 and ginsenoside rg3
| Article | Year |
|---|---|
Ginsenoside Rg3 promotes Fc gamma receptor-mediated phagocytosis of bacteria by macrophages via an extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent mechanism.
Topics: Animals; Bacteria; Cells, Cultured; Ginsenosides; Imidazoles; Macrophages; Male; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; p38 Mitogen-Activated Protein Kinases; Phagocytosis; Phosphorylation; Pyridines; Receptors, IgG; Signal Transduction | 2019 |